A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL

  • STATUS
    Recruiting
  • End date
    May 5, 2025
  • participants needed
    300
  • sponsor
    Sun Yat-sen University
Updated on 23 January 2021
cancer
hodgkin's disease
lymphoblastic lymphoma
PTEN

Summary

With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children. In recent years, the criteria for clinical staging and efficacy evaluation of NHL in children have been updated. Recent clinical studies of COG in the United States and LMB in France have confirmed that molecular biological markers such as Notch1, PTEN and LOH6q are significantly associated with the prognosis of T-lymphoblastic lymphoma (T-LBL). These molecular biological markers should be included in the new risk stratification system. High-intensity treatment of high-risk patients will improve survival. Recent studies have also suggested that PET/CT is helpful in evaluating residual lesions in patients with lymphoma after chemotherapy. In order to keep pace with the times in the diagnosis, clinical staging, risk stratification, efficacy evaluation and treatment of NHL in children. SCCCG-LBL-2017 was formulated by South China Children's Cancer Group of Non-Hodgkin lymphoma, which mainly updated in clinical staging, efficacy evaluation, risk stratification, treatment,etc..

Description

Research purpose:

  1. To investigate the efficacy and safety of SCCCG-LBL-2017 in Chinese children with LBL.
  2. To explore the feasibility of risk stratification of T-LBL by combining genotyping.
  3. To investigate the correlation between MDD and MRD in lymphoblastic lymphoma and prognosis.
  4. To investigate the role of PET/CT in the assessment of residual lymphoblastic lymphoma.
  5. To explore the effect of reducing HD-MTX dosage and shortening maintenance therapy time on the efficacy and survival of low-risk LBL patients.
  6. To explore the effect of prolonging the duration of maintenance therapy on the efficacy and survival of high-risk LBL patients.

Details
Condition Lymphoma, Non-Hodgkin's Lymphoma, Pediatric Cancer, Childhood Cancer, PTEN Loss, Lymphoblastic Lymphoma, Childhood, NOTCH1 Gene Mutation, Lymphoblastic Lymphoma, Childhood, non-hodgkin's lymphoma (nhl), Lymphoblastic Lymphoma, Childhood
Clinical Study IdentifierNCT03971318
SponsorSun Yat-sen University
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age < 18 years old
Pathologically confirmed lymphoblastic lymphoma
Newly diagnosed patients
Informed consent of guardian of children patients -

Exclusion Criteria

Age > 18 years old
Recurrent lymphoblastic lymphoma
Secondary immunodeficiency
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note